Skip to main content
ACRV
NASDAQ Life Sciences

Acrivon Q3 Loss Narrows to $17.9M; $77.8M Cash Funds Operations Into Q4 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.45
Mkt Cap
$62.566M
52W Low
$1.27
52W High
$3.56
52W Position info
14% above low
Off High info
59% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ACRV is trading near its 52-week low of $1.27 (14% above the low).

Summary

Acrivon reported a Q3 2026 net loss of $17.9 million and $77.8 million in cash, enough to fund operations into Q4 2027, with the ACR-368 Phase 2b interim analysis still expected in the fourth quarter of 2026.


Key Events · Earnings and Guidance · ACRV

  • Q3 Loss Narrows Slightly

    Net loss was $17.9 million for the quarter ended September 30, 2026, versus $18.2 million a year earlier; R&D rose to $14.5 million from $13.6 million while G&A fell to $4.0 million from $6.0 million.

  • Cash Runway Into Q4 2027

    Cash, cash equivalents and investments totaled $77.8 million as of September 30, 2026, which management expects to fund operating expenses and capital expenditures into the fourth quarter of 2027.

  • ACR-368 Interim Analysis Due Q4 2026

    The prespecified simultaneous interim analysis across the all-comer serous endometrial cancer arms of the Phase 2b study, plus an update of the OncoSignature-positive Arm 1, is expected in the fourth quarter of 2026, with full enrollment of Arm 3 or Arm 4 also targeted then.

  • New CDK11 Candidate ACR-7280 Nominated

    Acrivon nominated oral CDK11 inhibitor ACR-7280 for IND-enabling studies, with an IND submission to the FDA planned for the first half of 2027 in AML and peripheral T-cell lymphoma.


Analysis · ACRV · Life Sciences

The cash balance is the headline here: $77.8 million keeps Acrivon funded into the fourth quarter of 2027, past the ACR-368 Phase 2b interim analysis expected in Q4 2026 and the ACR-2316 expansion readouts targeted by mid-2027. Third-quarter loss came in at $17.9 million, slightly better than the $18.2 million loss a year ago, as R&D spending rose to $14.5 million from $13.6 million while G&A fell to $4.0 million from $6.0 million. The quarter also added a new pipeline asset, the oral CDK11 inhibitor ACR-7280, with an IND filing planned for the first half of 2027, and management reiterated that the ACR-525 JAK1 program will seek FDA alignment on a Phase 2 eosinophilic esophagitis trial in the first quarter of 2027. With the stock at $1.45 and a small market capitalization, the runway statement matters more than the modest loss improvement — it removes near-term financing pressure ahead of the ACR-368 data.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ACRV was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.6M. The 52-week trading range was $1.27 to $3.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ACRV - Latest Insights

ACRV
Nov 16, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $1.45 info
Change: $0 (0%) info
Market Cap: $62.566M info
ACRV
Nov 10, 2026, 4:55 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.45 info
Change: -$0.150 (-9%) info
Market Cap: $62.566M info
ACRV
Nov 06, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.60
Real-time Price: $1.45 info
Change: -$0.150 (-9%) info
Market Cap: $62.566M info
ACRV
Nov 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.57
Real-time Price: $1.45 info
Change: -$0.120 (-8%) info
Market Cap: $62.566M info
ACRV
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.45 info
Change: -$0.270 (-16%) info
Market Cap: $62.566M info